Remibrutinib is a medication being studied for treating relapsing multiple sclerosis. It belongs to a class of drugs known as BTK inhibitors, which work by blocking specific proteins involved in inflammation. This medication aims to control the inflammatory activity in the brain and spinal cord of people with multiple sclerosis.

Ocrelizumab is an established medication used to treat relapsing multiple sclerosis. It works by targeting and reducing specific B cells in the immune system that are thought to contribute to nerve damage in multiple sclerosis. It is given through an intravenous infusion and is currently used as a standard treatment for multiple sclerosis.

Multiple Sclerosis (Relapsing) – A chronic neurological condition where the immune system attacks the protective covering of nerve fibers in the central nervous system. In the relapsing form, people experience distinct episodes of symptoms followed by periods of partial or complete recovery. During relapses, inflammation causes new damage to nerve cells, leading to various symptoms such as vision problems, muscle weakness, and coordination difficulties. Between relapses, patients may feel relatively well, though some symptoms might persist. The disease typically follows a pattern where new symptoms appear or existing ones worsen during relapses, which can last days to weeks.